A PSMA PET scan typically costs between $5,000 and $6,000 in the United States without insurance, with one multicenter study placing the average at $5,438.1National Library of Medicine. Cost-Effectiveness of PSMA PET/CT Versus Conventional Imaging Medicare and most private insurers cover the scan for approved indications, which drops the out-of-pocket cost to coinsurance after your deductible — often a few hundred dollars at a freestanding imaging center, more at a hospital.
What Drives the Cash Price
The tracer, not the imaging itself, is where the money goes. A Florida imaging center breaks the total down as roughly $1,000 for the PET scan and about $5,000 for the PSMA radiotracer, which is priced by the manufacturer.2PET Imaging Institute of South Florida. PSMA PET Scan FAQ That is why PSMA PET sits well above conventional staging: a CT scan combined with a bone scan averages $2,161 in the U.S., roughly $3,300 less per scan.1National Library of Medicine. Cost-Effectiveness of PSMA PET/CT Versus Conventional Imaging
If you are paying cash, ask the facility for an itemized estimate that separates the scan from the tracer. The tracer price is largely fixed, but the scan portion is where facilities differ.
Where You Have the Scan Done
Facility setting changes the bill significantly. One estimate puts the average PET scan at $7,275 in a hospital versus $2,550 at a freestanding outpatient facility.3Capitol Imaging Services. How Much Does a PET CT Cost Humana reports a similar pattern for its members: a national average of $1,599 at a hospital outpatient department against $920 at a freestanding center.4Humana. Medicare PET Scans
Those numbers reflect general PET scan pricing and may not include the PSMA tracer, which is billed separately. The point holds either way: if your physician gives you a choice of locations, the freestanding center is usually meaningfully cheaper.
What Medicare Pays
Medicare covers PSMA PET for two main indications: initial staging in patients with suspected metastasis who are candidates for definitive therapy, and detection of biochemical recurrence based on rising PSA. Gallium-68 gozetotide tracers are also covered to select patients for PSMA-directed radioligand therapy.5Palmetto GBA. PSMA PET Drugs and Biologicals
Under Original Medicare Part B, you pay 20% coinsurance after meeting the annual deductible ($283 in 2026). On the Humana averages, that works out to about $183 at a freestanding center or $319 at a hospital outpatient department.4Humana. Medicare PET Scans Those figures cover the scan only; the tracer carries its own cost-sharing, which can be substantial. Medicare Advantage plans may use different cost-sharing rules and often require prior authorization before the scan.
What Private Insurance Pays
Major private insurers generally cover PSMA PET when it meets medical necessity criteria, though the specifics vary. UnitedHealthcare’s Medicare Advantage policy defers to CMS National Coverage Determinations and Local Coverage Determinations for PET.6UnitedHealthcare. Radiologic Diagnostic Procedures Aetna routes oncologic PET imaging through eviCore by Evernorth guidelines, updated annually.7Aetna. Positron Emission Tomography
Your actual out-of-pocket depends on your plan’s deductible, coinsurance rate, and out-of-pocket maximum. On a scan totaling $5,000 to $6,000, a 20% coinsurance with an unmet deductible can produce a large bill. If you have already hit your out-of-pocket maximum for the year, you may owe nothing. Call your insurer, confirm the scan is in-network, and ask whether both the facility fee and the tracer are covered under the same cost-sharing.
Prior Authorization and Appealing a Denial
Prior authorization is a common requirement and a known source of friction. A 2023 survey of U.S. urologists found that 88% could order PSMA scans locally and 58% could get patients scanned within two to three weeks, but the authorization process itself demanded additional staff time.8Urology Times. PSMA Uptake, Access Appear High for US-Based Urologists Physicians are advised to document NCCN risk classification, specific PSA values indicating biochemical recurrence, and the clinical intent of the scan when submitting authorization requests.9Urology Times. PSMA PET Documentation of Patient Eligibility and Reimbursement
If your scan is denied, appeal. Across medical services broadly, more than half of appeals succeed, and more than half of denials are reversed during peer-to-peer review. Yet fewer than 1% of denials are ever appealed.10Prostate Cancer Research Institute. Insurance Denials Submitting appropriate use criteria from the Society of Nuclear Medicine and Molecular Imaging along with your clinical documentation strengthens the case.
Manufacturer Financial Assistance
Because the tracer is the dominant cost, the tracer manufacturers run patient support programs. Lantheus, which makes Pylarify (piflufolastat F 18), operates Lantheus Link, offering personalized help with financial aid options and referrals to outside assistance organizations. Patients enroll through their physician and can reach a Care Coordinator at 844-339-8514.11Lantheus. Patient and Caregivers Lantheus states that more than 90% of covered lives have access to Pylarify.12Pylarify. Order and Reimbursement Support
Blue Earth Diagnostics, which makes Posluma (flotufolastat F 18), provides Field Reimbursement Managers who help with prior authorizations, billing, and appeals, plus a reimbursement support helpline.13Posluma. Reimbursement and Support Neither manufacturer publicly advertises a simple copay card, so contact these services directly to find out what applies to your situation.
Is It Worth the Higher Price Over Conventional Imaging?
PSMA PET costs more than CT and bone scans but detects cancer that conventional imaging misses. The Australian proPSMA trial found PSMA PET/CT was 27% more accurate overall, with sensitivity for distant metastases at 92% versus 54% and for nodal metastases at 83% versus 23%. In that Australian analysis, PSMA PET/CT actually cost less per scan than conventional imaging (AUD $1,203 versus AUD $1,412), making it the economically dominant option in that system. The authors cautioned that those results may not transfer to the United States, where PET pricing runs considerably higher.14UroToday. Cost-Effectiveness of PSMA PET-CT Compared With Conventional Imaging
A European analysis found that PSMA PET at initial staging saved €674 per patient by avoiding unnecessary lymph node dissections and inappropriate treatments, though a small quality-of-life trade-off from false positives left the overall cost-effectiveness question unsettled at current accuracy levels.15National Library of Medicine. Cost-Effectiveness of PSMA-11 PET/CT at Initial Prostate Cancer Staging For an individual patient, the practical question is narrower: whether your insurer agrees the scan is medically necessary, which usually depends on your risk category and PSA trajectory. If it does, your cost-sharing is modest. If it does not, the full cash price is on you — and that is where appeals and manufacturer assistance matter most.